Veloce BioPharma Announces Positive Phase 2b Study Results for VBP-926 (Topical Povidone-Iodine in a Novel Non-Aqueous Vehicle) in Subjects with Chemotherapy-Associated Paronychia

Corporate Breaking News

Home : Veloce BioPharma Announces Positive Phase 2b Study Results for VBP-926 (Topical Povidone-Iodine in a Novel Non-Aqueous Vehicle) in Subjects with Chemotherapy-Associated Paronychia

Oct 03 2018	Veloce BioPharma Announces Positive Phase 2b Study Results for VBP-926 (Topical Povidone-Iodine in a Novel Non-Aqueous Vehicle) in Subjects with Chemotherapy-Associated Paronychia
Veloce BioPharma's VBP-926 (Povidone-Iodine) Demonstrates Statistically Significant and Clinically Significant Results in Phase 2b Study for Chemotherapy-Associated Paronychia Positive clinical results provide basis for pivotal Phase 3 clinical trials FORT LAUDERDALE, Fla., Oct. 3, 2018...


Source:https://www.prnewswire.com:443/news-releases/veloce-biopharma-announces-positive-phase-2b-study-results-for-vbp-926-topical-povidone-iodine-in-a-novel-non-aqueous-vehicle-in-subjects-with-chemotherapy-associated-paronychia-300723415.html

Related News
» OMRON to Introduce NX-series Safety Network Controller That is World's First (*1) to Support Two Industrial Safety Networks » Landmark study in the British Journal of Psychiatry Open highlights how Ieso's digitally-enabled therapy can transform mental health treatment